Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer.

Eur J Nucl Med Mol Imaging · 2019 · PMC6820371 · PMID 31134301

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

There was a clear trend of enhanced tumor growth inhibition and increased survival after application of 161 Tb-PSMA-617 as compared to 177 Lu-PSMA-617 at all activity levels ( Supplementary material , Fig.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.